ICU Stock — SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation (ICU)

Updated October 16, 2026.

ICU is a Stock. Total return is -99.9% over the past 5.6 years, 210.4 points behind SPY at 110.5%.

SeaStar Medical is a clinical-stage healthcare company developing a proprietary selective cytopheretic device platform designed to treat hyperinflammation and its effects on vital organs, with lead candidates targeting acute kidney injury in pediatric and adult patient populations. The company does not currently distribute to shareholders. SeaStar Medical appeals to investors seeking exposure to early-stage medical device innovation rather than current income.

ICU performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.9% over the past 5.6 years, 210.4 points behind SPY at 110.5%. Over the past year its total return — price change plus distributions reinvested — is -54.0%. Its deepest 1-year drawdown was 65.0%.

ICU key facts

Asset type

Stock

Asset class

Equity

Inception date

03/18/2021

Distribution frequency

None

Last close

$2.90 (as of 2026-10-16)

Market cap

$15,256,445

Average volume

140462.0

Beta

-1.066

Payout ratio

0.0%

EPS

$-3.09

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ICU risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 65.0%.

Who may consider ICU — and who may not

It is a weaker fit for investors who need monthly cash flow (ICU does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ICU

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions